Gemcitabine/Irinotecan/ZD1839 vs Paclitaxel/Carboplatin/Etoposide/ZD1839 in Carcinoma of Unknown Primary Site
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- John D. Hainsworth, MD
SCRI Development Innovations, LLC
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
31 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Northeast Alabama Regional Medical Center
Anniston, Alabama, United States
- Clearview Cancer Institute
Huntsville, Alabama, United States
- Southern Cancer Center, Sacred Heart Heath System Medical Oncology Group
Mobile, Alabama, United States
- Northeast Arkansas Clinic
Jonesboro, Arkansas, United States
- Tower Oncology
Beverly Hills, California, United States
- Watson Clinic Center for Cancer Care and Research
Lakeland, Florida, United States
- Mercy Hospital Miami
Miami, Florida, United States
- Florida Hospital Cancer Institute
Orlando, Florida, United States
- Phoebe Cancer Center
Albany, Georgia, United States
- Northeast Georgia Medical Center
Gainesville, Georgia, United States
- Wellstar Cancer Research
Marietta, Georgia, United States
- Oncology Hematology Associates of Sw Indiana
Evansville, Indiana, United States
- Graves-Gilbert Clinic
Bowling Green, Kentucky, United States
- Consultants in Blood Disorders and Cancer
Louisville, Kentucky, United States
- Terrebonne General Medical Center
Houma, Louisiana, United States
- Mercy Hospital
Portland, Maine, United States
- Grand Rapids Clinical Oncology Program
Grand Rapids, Michigan, United States
- St. Joseph Mercy Oakland Hospital, Cancer Center
Pontiac, Michigan, United States
- Jackson Oncology Associates
Jackson, Mississippi, United States
- Montana Cancer Institute Foundation
Missoula, Montana, United States
- Methodist Cancer Center
Omaha, Nebraska, United States
- Aultman Hospital
Canton, Ohio, United States
- Oncology Hematology Care
Cincinnati, Ohio, United States
- Consultants in Medical Oncology and Hematology
Drexel Hill, Pennsylvania, United States
- Reading Hospital Regional Cancer Center
West Reading, Pennsylvania, United States
- Spartanburg Regional Medical Center
Spartanburg, South Carolina, United States
- Kingsport Hematology-Oncology
Kingsport, Tennessee, United States
- Thompson Cancer Survival Center
Knoxville, Tennessee, United States
- Tennessee Oncology, Pllc
Nashville, Tennessee, United States
- South Texas Oncology and Hematology
San Antonio, Texas, United States
- Cancer Outreach Associates
Abingdon, Virginia, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 30 Sept 2003
- Primary completion
- 30 Sept 2008
- Completion
- 30 Jun 2009
- Last update posted
- 3 May 2013
- Registered enrollment
- 198
- Registry id
- NCT00193596
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.